Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 4 citations in OpenAlex.
Paeton L WantuchDepartment of Pediatrics, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-6993-6320
Cory J KnootOmniose, St. Louis, MO, 63110, USA.
Lloyd S RobinsonOmniose, St. Louis, MO, 63110, USA.
Evgeny VinogradovNational Research Council Canada, Human Health Therapeutics Centre, Ottawa, ON K1A 0R6, Canada.
Nichollas E ScottDepartment of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, VIC 3010, Australia.ORCID 0000-0003-2556-8316
Christian M HardingOmniose, St. Louis, MO, 63110, USA.
David A RosenDepartment of Pediatrics, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, MO 63110, USA.
Washington University in St. Louis · USNational Research Council Canada · CAThe University of Melbourne · AU
Funding
A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infectionsR42AI165116 · NIAID · VAXNEWMO, LLC · PI Christian Harding · 2022 to 2026
$3.6M
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent KlebsiellaR01AI175038 · NIAID · WASHINGTON UNIVERSITY · PI ROSEN, DAVID A. · 2023 to 2025
$3.5M
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infectionsR41AI167078 · NIAID · VAXNEWMO, LLC · PI HARDING, CHRISTIAN · 2022 to 2023
$593k
Immune recognition of Klebsiella pneumoniae O2v1 and O2v2 O-antigen subtypesR21AI166090 · NIAID · WASHINGTON UNIVERSITY · PI ROSEN, DAVID A. · 2023 to 2024
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A heptavalent O-antigen bioconjugate vaccine exhibits differential functional antibody responses against diverse · full record | OpenQuestion